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Abstract: Paper-based sensors and assays have been highly attractive for numerous biological
applications, including rapid diagnostics and assays for disease detection, food safety, and clinical
care. In particular, the paper immunoassay has helped drive many applications in global health due
to its low cost and simplicity of operation. This review is aimed at examining the fundamentals of the
technology, as well as different implementations of paper-based assays and discuss novel strategies
for improving their sensitivity, performance, or enabling new capabilities. These innovations can
be categorized into using unique nanoparticle materials and structures for detection via different
techniques, novel biological species for recognizing biomarkers, or innovative device design
and/or architecture.
Keywords: paper-based immunoassays; lateral flow assay; biological sensors; dipstick assay;
rapid diagnostics
1. Introduction
Diagnostics are critical for healthcare to confirm or help diagnose a patient. Typically diagnostics
are lab-based, often requiring skilled personnel and can be labor intensive. This increases the time and
cost of diagnosis and limits their accessibility. The problem is accentuated in more rural communities
and in middle and lower income countries where point of care (POC) facilities are limited in equipment
and resources to train personnel. This can present a serious challenge for local and lower income
healthcare systems as doctors lose faith in pathological evidence and fall back on presumptive
diagnosis [1].
For example, both dengue and Zika viruses inhabit tropical climates and are transmitted by the
Aedes Aegypti and Aedes albopictus mosquito. They have similar early stage symptoms, muscle and
joint pain, rashes, headaches, fever and other flu-like symptoms, but treatment for both are very
different [2]. While for most adults, infection with Zika does not require hospitalization, whereas
dengue is more severe leading, to hospitalization for ~100 in 100,000 cases, or death in ~5 in 100,000
cases [3,4]. Furthermore, early stage symptoms of both viral infections can be mistaken other infections,
such as chikungunya [5] and Spondweni viruses [6]. While Zika can be mild for adults, there is
a confirmed causal relationship between women exposed during pregnancy and microcephaly in
the child [7,8]. Differentiating between these and many other diseases is crucial for patient health
outcomes, disease surveillance, and emergency preparedness, but often difficult [9].
It is estimated that the global biosensor market will grow by over 70% by 2022 from 15.6 billion
USD in 2015 to over 27 billion USD [10–12]. The majority of the market share (66% in 2013 [10]) is
in medical diagnostics, particularly in diabetes, cancer and infectious disease detection. There has
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been a steep increase in the number of developed diagnostics tools, devices and procedures [13,14].
Advancements in technology and the push for new, low cost, user-friendly POC devices have been
cited as the main drivers [10,12]. The World Health Organization (WHO) has established guidelines
for diagnostics in the developing world, which are that they must be Affordable, Sensitive, Specific,
User Friendly, Rapid and Robust, Equipment Free, Deliverable (ASSURED). The ASSURED criteria are
difficult to fully meet, but paper-based assays have the potential to meet most of these requirements [15].
Presently the most commonly used diagnostics are laboratory based techniques, such as PCR [16],
enzyme-linked immunosorbent assay (ELISA) [17,18], Western blot [17,18] and cell culture assays.
However, paper-based assays are an important technology that is growing.
1.1. Paper-based Immunoassays
Paper-based assays are paper strips which can test for the presence of a biomarker in a biological
fluid. Most paper-based assays are immunoassays, i.e., they use antibodies to bind to the biomarker
of interest. They can be read out by eye, which is due to the use of gold nanoparticle (NP)-antibody
conjugates that cause a strong color to appear at a test line.
Though variations exist in their most basic form paper-based assays consist of a nitrocellulose or
glass fiber substrate; NPs functionalized with antibodies, or immunoprobes, and a capture antibody
printed onto the substrate. Due to the small number of components, lack of moving parts, and minimal
quantities of reagents, single assays are low cost and easy to mass produce [19,20].
A wide range of molecules can be bound to NPs to form the probes used in paper-based assays,
to enable numerous possible targets and applications. Furthermore, multiple probes functionalized
with different molecules can be used to simultaneously test for a number of targets [20–22]. Device
design geometry can be augmented to suit use-specific requirements [19,23]. Paper-based assays do
not require power or additional reagents to run, further increasing applicability and reducing costs.
A single assay can be complete within minutes. Furthermore, test results can be easily read and
understood by non-specialists (Figure 1). The biggest advantages of paper-based assays are their ease
of use, portability and low cost. Due to the wide applicability of bioassays and broad background of
end users, and these assays can provide an understandable yes/no diagnosis.
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Figure 1. (A) Pregnancy test and (B) structure of a lateral flow assay. From Miocˇevic´, O. et al. [24].
As a result, paper-based assays are considered a critical POC device with the potential to expedite
testing times, reduce costs, and enable clinicians to make faster treatment decisions thus improving
patient healthcare outcomes [25]. Though paper assays have been successful in many areas, the field is
multidisciplinary and complex, and as a result it can be difficult to identify key gaps. This review aims
to provide an understanding of the fundamentals of paper-based assays and introduce the reader to
various related contemporary ideas and challenges. We first discuss the fundamentals and define core
concepts, such as what a paper-based assay is, fluid flow in paper matrices, and common nanoparticle
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readouts used. This is followed by a section on challenges designed to present the reader with a set of
common pitfalls encountered when designing a new paper-based assay.
1.2. Commercial Applications
The simplicity of use for paper-based assays has made them a potentially transformative
technology in a variety of fields. In addition to the most commonly used assay, the over-the-counter
pregnancy test, numerous paper-based assays are commercially available (mostly lateral flow type
systems) or are in various stages of development (mostly newer designs which include patterning
on paper or enhanced signal readouts) for agriculture [26–28], environmental protection [29,30],
poison [31–33], antibiotics [34], infectious disease agents [35,36], noninfectious diseases [37], and many
others. In agriculture, tests can be used for compliance to regulatory adherence [27] in soil and water
quality analysis [30].
1.3. Disadvantages
While the simple design and use of paper-based assays is their most attractive feature, it also
presents a number of challenges and disadvantages. There are a number of reviews which perform a
cost-benefit analysis of paper-based assays [38,39], including strengths, weaknesses, opportunities and
threats (SWOT) analysis [35,40].
Qualitative instead of quantitative readouts [35,41]. The POC format often allows only a
qualitative or semi-quantitative result. Some have attempted to resolve this by introducing cell
phone attachments which allow for quantification of the test line intensity and thus more accurate
result analysis [42].
Low sensitivity [43]. While paper assays have benefits of a simple test methodology, do not
require instrumentation, have a simple readout and need low sample volumes, these can reduce assay
sensitivity. Visual readout means that target biomarkers must be present at a sufficient concentration.
Low sensitivity can be ameliorated by signal enhancement techniques [44], improving test design [45]
changing the readout type, or the use of instrumentation.
Test variability. Variability of paper-based assays can be high, resulting from complex samples,
environmental factors, such as temperature and humidity, paper porosity, and probe instability [38].
Single use, not high throughput [35]. Paper-based assays are often by design single use devices
and thus not meant for analysis of multiple samples.
2. Components of Paper-Based Assays
Understanding the fundamental principles and controls has enabled researchers to develop a
wide range of applications of paper-based assays, such as incorporation of novel probes, strategies for
increasing sensitivity, and complex multilevel paper analytical devices [40]. Here we review the basic
properties of paper-based tests.
2.1. Paper-Based Assay Formats: Dipstick and Lateral Flow Configurations
Paper-based assays are comprised of a nitrocellulose substrate (or strip), an immunoprobe (often
gold NP based) and a sample solution (Figure 2a). Antibodies are printed onto the test strip, one which
recognizes the biomarker-antigen or antibody- (on the test line, blue in Figure 2b), and another which
recognizes the antibody bound to the NP (on the control line, green in Figure 2b). Readout is based on
the presented pattern, where the test line indicates the presence/absence of the biomarker and the
control line indicates that the test has run properly.
There are two main assay formats, either dipstick or lateral flow (Figure 2b,c). For lateral flow
assays (LFAs), the strip consists of a sample pad, conjugation pad, test area and an absorbent pad.
After the sample is deposited onto the pad it runs through the paper due to capillary flow. Pre-dried
immunoprobes on the conjugation pad are rehydrated and start diffusing in the solution and bind
with the antigen (Figure 2c). An absorbent pad attached to the nitrocellulose strip acts as a fluid sink,
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providing the driving force for capillarity. In a dipstick assay there are no sample or conjugation pads,
where the immunoprobes are mixed with the sample and the bottom of the strip is immersed in this
solution (Figure 2b).
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Figure 2. (a) Figure legend. (b) Schematic representation of a test run and result readout of a dipstick
assay configuration. (c) Schematic representation of a test run and result readout of a lateral flow assay
(LFA) configuration.
There are two binding configurations for immunoassays. A sandwich configuration is when
the presence of the target antigen results in simultaneous binding to the immunoprobe and capture
antibodies (Figure 3a) [38,41,46,47], while the control antibody binds to the probe only. A positive
recognition event is expressed as the appearance of a line in the test area (Figure 3a). If the target is too
small to bind two antibodies simultaneously, or has epitopes for that inhibit one another, a competitive
format can be used [38,41,46–48]. A pre-bound immunoprobe is present at the test line, and when the
target molecule is present it displaces the immunoprobe, resulting in the disappearance of color from
the test line (Figure 3b).
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2.2. Paper Assay Components
A paper assay diagnostic is composed of several components:
2.2.1. Paper Substrate
Paper is the most commonly used substrate for NP immunoassays [19,20,41,49]. Because it is
porous, liquid can flow through it without external pumping [19]. It is biologically compatible and does
not strongly interact with biomolecules and immunoprobes within its matrix, but can be chemically
modified if required [49]. Paper also has a large surface area which allows the immobilization of a
large number of sensor molecules [49]. It is white which leads to better contrast.
Paper is thin, light weight, flexible, durable, and easy to produce, store and manipulate. It is
available in a wide variety of sizes, thicknesses and shapes which allows for a measure of control
over test running conditions [49]. Furthermore, paper has a long history of application in chemistry,
so there is an established production and supply infrastructure in place. This makes it widely available
in a variety of pore size, types and chemical modifications (e.g., nitrocellulose) [20,49,50]. Instruments
to shape paper, such as laser cutters, are affordable user friendly [20]. Finally, it can be produced and
disposed of in biologically friendly and safe ways [19].
There are several relevant parameters of the paper substrate. Porosity, or void or pore volume
fraction, is a measure of the air filled and solid fractions of paper. It is defined as ϕ = VVVT × 100, where
VV is void volume and VT the total volume of the paper [51]. Alternatively it is defined using the
density of the soli component wood fiber used to make the paper and the density of he paper itself
as ϕ = 1− ρpaperρsolid wood f iber , where ρpaper and ρsolid wood f iber are th density of the woo fiber and pa er,
resp ctively [49]. Porosity can be brok n down i to pore size, the averag iameter of pores in the
paper, and pore size distribution, the distribution of pore sizes in the medium.
Measurement of the three parameters requires multiple methods, including mercury porosimetry
and gas adsorption [51,52]. Often pore sizes provided by manufacturers are a bulk average [53].
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2.2.2. Reporters
Reporters indicate the presence of the target antigen, and are linked to the antibody or other
binding moiety. NPs are often used as reporters, with gold NPs the most prevalent as they have a high
signal to noise ratio for visual readouts. NPs of other materials have been used, such as dye-infused
cellulose particles [54], and quantum dots can be used to provide a fluorescent signal [55].
The immunoprobe is comprised of a NP core, a surface coating ligand to stabilize the NP or
enable chemical grafting, and a biomolecule, such as an antibody that binds specifically to the target
biomarker (Figure 4). Chemical grafting and physical adsorption are the two strategies used to bind
the active molecule to the core.
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NPs offer a high surface area and can be attached to many different binding species (antibodies,
peptides, DNA, etc.). They are also attractive due to their size-tunable properties, ability to encapsulate
and protect many fluorescent entities, and general structural robustness [14].
Multiple factors need to be considered when designing an immunoprobe, including stability in
relevant media with respect to both aggregation and dissolution, biomolecule adsorption on its surface,
denaturation and accessibility the surface bound antibody, and its overall ability to bind the antigen.
In this context the minimum requirements for an immunoprobe to be applicable in paper-based assays:
• Surface bound antibodies are able to bind antigens, i.e., their epitope is still accessible
and functional.
• Immunoprobes interact with the environment in a way which does not impede the antibody’s
ability to bind the antigen, e.g., particles do not aggregate in relevant conditions.
• Immunoprobes interact with the paper medium weakly and without undesirable precipitation,
and can diffuse through the paper strip while producing minimal background.
Due to the la ge number of antigen targets and NP types in pape assays, there is a enormous
number of immunoprobe types in literature. In a 2017 review Ferka Z. et. al. identified 3300 relevant
papers published between 2012 to 2016 [47].
Rep rters can also be chemical reagents used, including pH indicators, dyes, antibodies,
and enzyme [43]. Small molecules are sometimes nonideal due to the low signal-to-noise of a
single molecule. Furthermore it is a commo practice i paper production to add fluorophores to m ke
the product look whiter, which could cause a high background [49].
2.2.3. Antibodies that Bind to the Target
When creating a diagnostic for a pathogen of an infectious disease, one must choose a target
biomarker which must have clinical relevance and be present at high enough concentrations in the fluid
of interest. For viral or bacterial infections, one can detect the virus or bacteria present in the patient,
usually via the envelope proteins or the genetic material of the pathogen. Alternatively, the immune
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response of the patient can be used for diagnosis, where the antibodies generated in response to the
infection are detected [54,56]. In each case, antibodies specific for the target biomarker are attached to
the reporter and also immobilized on the strip.
Antibodies are proteins produced by a host in response to an antigen, and thus can bind to
it with specificity. Antibody-antigen interactions are characterized by high affinity and specificity,
which makes them an attractive binding species. They are a family of proteins which are referred
to as immunoglobulins (Igs) which are produced by differentiated B cells. There are five primary
classes of Igs: (i) IgA is the second most common in human serum and is most prevalent in human
secretions, such as saliva, tears, etc.; (ii) IgD is found in very low concentrations in human serum
and the least understood; (iii) IgE is least abundant in human serum; (iv) IgG is the most common in
human serum; (v) IgM is the third most common in human serum, but is expressed at the early stages
of infection, i.e., on the surface of immature and mature B cells. Antibodies can be either monoclonal
or polyclonal, where monoclonal antibodies react with a single, defined site on the antigen (an epitope)
while polyclonal antibodies react to multiple sites on the antigen.
Detecting the antigen vs. the antibody depends on disease pathology. For flaviviruses, such as
dengue, the antigen nonstructural protein 1 (NS1) serves as a good biomarker, because it is secreted
early after infection (within ~1–2 days) when patient symptoms are still non-specific Also, dengue
NS1 is present at high concentrations in the blood [56]. Lyme is another good example of this dynamic.
Presently the Center for Disease Control and Prevention (CDC) recommends a two tier (ELISA and
Western blot) serologic analysis. Due to the nature of the cause (Borrelia Burgdorferi) most available tests
are for IgG/IgM. This strategy is characterized by high specificity (>98%) and reasonable but variable
sensitivity (30–100%) depending on proper application, type of test, and disease stage [18,57–59].
However, as detection relies on the host immune response, it is ineffective until a few weeks after
the infection [18,60]. Borrelia can affect the immune system and in particular IgG production [61–64]
and less so for early IgM production. Furthermore, anti-Borrelia IgG can persist for months to years
after the infection has cleared, or could be the result of a Lyme vaccine, thus resulting in a false
positive [17,18,58]. However, especially at late stages Borrelia is mostly found in low numbers in
collagenous tissue and thus difficult to detect directly. An assay for a Lyme antigen as opposed to
Lyme antibodies would lead to faster and possibly more accurate diagnosis, and potentially lower
medical costs and improved patient health outcomes.
For cases when nucleic acids are the target biomarkers, such as detection of viruses or bacteria
themselves, or in the detection of siRNA, the capture molecule can be a complementary nucleic
acid [39,44,56,65]. This often occurs downstream of PCR or another amplification technique in order
to amplify the target nucleic acid. Design of capture nucleic acids can be easily tailored to increase
affinity by extending the complementary sequence.
3. Metrics for Paper Assay Performance
3.1. Description of Target-Antibody Binding
For binding events it is useful to quantify the affinity of the antigen-antibody interaction, as it
is occurring at the test line and is responsible for the signal. Because the antibodies are tethered to
the nitrocellulose or a NP, the antibody-antigen affinity may not be the same for the free species in
solution. Towards this end, a modified Langmuir model can be used to qualitatively evaluate binding
affinity [66].
The model utilizes the surface adsorption model where the free species is the NP-Ab/antigen
complex, and describes its binding to the immobilized Ab on the test line, or successful sandwich
immunoassay formation (Figure 5). A free species A can bind to a surface species S, to form a surface
immobilized species, SA (Equation (1))
S+A↔ SA (1)
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The fraction of occupied sites, Θ, can be measured as a function of the concentration of A to obtain
an expression containing KD, the equilibrium dissociation constant (Equation (2)):
Θ =
nK[A]
1+K[A]
, (2)
where the equilibrium dissociation constant, KD, is (Equation (3)):
KD =
[S][A]
[SA]
, (3)
which describes the affinity of A for S. Here, the Langmuir surface model describes the second binding
event, so A is taken to represent the NP-Ab/antigen complex and S is the immobilized antibody, and the
sandwich immunoassay represented by SA (Figure 6b). The concentration of SA is proportional to the
test line intensity, which is proportional to the number of NPs at the test line due to target binding.
It is important to note that the model assumes that the surface bound species SA are independent
and do not influence binding of adjacent sites, and that surface binding can result only in a monolayer
and equilibrium binding conditions [67]. The binding affinity constant is an effective binding constant,
KDeff, as the binding events are lumped together as binding of the NP-antibody/antigen complex to the
immobilized antibody. Nevertheless, KDeff can still be used to compare how binding affinity changes
under different conditions, such as NP surface chemistry, NP properties, and running conditions.
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3.2. Sensitivity and Specificity
Paper-based assay performance is assessed by their sensitivity and specificity [68]. Sensitivity is
a measure of the ability of the assay to correctly detect the target, and calculated using Equation (4)
(Table 1) as a percentage. An important element of sensitivity is the limit of detection (LOD) [47,69,70]
defined as the concentration at which there is a signal that is significantly higher than the background.
Typically this is defined as 3X the standard deviation of the blank above the baseline [71]. LOD
depends on the antibody-antigen affinity and immunoprobe physical properties (optical absorption for
colorimetric readouts). Other factors include paper substrate properties, number and state of printed
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detector molecules the substrate, immunoprobe stability, ability of both printed and immunoprobe
bound detector molecules to the target, readout method, competition with free target molecules [36,72].
Table 1. Definition of sensitivity and specificity.
Sensitivity [73]
Probability of Detecting the Target Molecule when
Present
Specificity [73]
Probability of not Detecting the Target Molecule
when Absent
Sensitivity =
NTrue Positives
NTrue Positives+ NFalse Negatives
(4)
Specificity =
NTrue Negative
NTrue Negative+ NFalse Positive
(5)
NTrue Positives: The number of times the test detected
the target molecule in a sample when it was present.
NFalse Negatives: The number of times the test failed to
detect the target molecule when it was present.
NTrue Negative: The number of times the test did not
detect the target molecule in a sample when it was
not present.
NFalse Positive: The number of times the test detected
the target molecule when it was not present.
Specificity is a measure of the likelihood of the test to give a false positive (Table 1, Equation (5)).
For example, if a test gives a positive result for a sample which does not contain the target molecule
half of the time, it has a specificity of 50%. Similarly to sensitivity and LOD, specificity depends on a
wide range of factors, but especially cross reactivity and nonspecific binding either of molecules to the
immunoprobe surface or of the immunoprobe on the paper.
4. Factors Impacting Paper Assay Performance
4.1. Fluidic Properties of The Paper Strip
The rate at which the fluid flows through the strip can influence assay performance [74,75].
Slowing down flow can improve antigen binding with the immobilized antibodies and immunoprobe.
Control of flow can be used to improve reagent mixing or even achieve multiple reactions in a
sequential and timed order [45,76–79]. Typically, in the construction of a paper-based assay, design of
the strip can be used to control flow through the following means:
Flow rate control through strip geometry. Widening the strip results in a slower flow rate and
thus longer time for reactions to occur, but also increases sample and reagent volume requirements
and test time [74]. In extreme cases it may result in uneven flow [49,74,76,80]. Increasing the strip
length inversely impacts fluid flow [80,81] and can increase the probability of a successful antigen
binding, but may also increase the probability of NPs getting stuck in the paper matrix. Hence there
is a maximal desirable channel width and length for a given use. Some [76,80,82] have developed a
mixed geometry with narrow channel regions and wide control and test regions (Figure 6b,c). This
allows for slower flow as the sample passes over the printed antibodies to increase the success rate
of binding.
Flow rate control through paper porosity and morphology. Paper is composed of cellulose
fibres, which are hollow tubes with an average length of 1.5 mm, width of 20 µm and wall thickness of
2 µm [49]. The paper pore size distribution is largely dependent on the production method and post
production treatment [11,75]. Nitrocellulose is predominantly used compared to cellulose [75], where
the hydroxyl groups in cellulose are replaced with nitride groups. Consequently, the pore size of the
paper reduced from an average of tens to hundreds of µm to hundreds of nm, its surface becomes more
hydrophobic and its structure becomes amorphous [20,43,83] (Figure 6a). The size and morphology of
nitrocellulose pores are dependent on casting conditions, such as water content and additives [75].
Pore size impacts not only fluid flow but also assay dynamics [84]. Small pores may cause
immunoprobes to get stuck in the matrix, while larger pores may result in an increase of test surface
area where a binding event can occur. Furthermore, paper is anisotropic [49], where the preferential
fiber orientation can impact fluid flow [19].
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4.2. Sample Preparation
Paper-based immunoassays usually require the addition of a pre-treated biological sample (blood,
urine, saliva, and others) in order to flow properly throughout the assay. Although a biological matrix
has proven to improve the performance of LFAs [66], typically blood-based tests require a sample
preparation step to remove red blood cells that can interact non-specifically with the NP probes and
result in false positives. This is conducted either by a pretreatment of the fresh blood with anticoagulant
molecules (e.g., heparin) and further centrifugation of blood cells (plasma) or by the centrifugation of
blood after coagulation to eliminate not only blood cells but also coagulated material (serum). In an
attempt to eliminate this extra step which requires equipment that may not be accessible in certain
POC facilities, some paper-based assays have included a paper fiber matrix that retains blood cells [86].
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The eluted solution (plasma) flows through capillarity downstream this step and functions as a typical
LF test.
5. Novel Modifications of Paper-Based Assays
While paper-based assays have the potential to transform POC diagnostics, there are still
many approaches being studied to improve their performance. Presently, multiple strategies are
in development to address this issue varying from improving and understanding immunoprobe
design and test modification, to implementing smartphone and other affordable instrumentation for
more advanced readout (Table 2).
5.1. Modifications and Improvements of Paper-Based Assays
5.1.1. Paper Enhancements
Paper-based immunoassays are analogues of ELISA reactions. Running a bulk ELISA requires
a stepwise protocol of mixing of solutions in vessels, where reactions must occur sequential after
prescribed time periods. The kinetics of the reactions influences the assay sensitivity, so the ability to
tune the reaction timings can be used to optimize the assay. Because of this, the ability to introduce
timing mechanisms in a paper assay enables the ability to tune and optimize the sensitivity of the
assay. There are many different ways in which paper assays can be modified for their fluidic structures
to introduce mechanisms for timing of the reaction to enhance the sensitivity, leverage the kinetics of
the reactions.
Flow rate control through additives. For some applications, e.g., simultaneous detection of
multiple antigens, the use of a single sheet of paper is preferred. Multiple centers and/or fine
control over liquid flow can be achieved through printing of different products onto the paper
substrate. This could be due to the formation of impassable hydrophobic barriers, such as those
made from wax [23,43,74,87–89] or dissolvable materials, such as dried sugar lines, designed to slow
fluid flow [80,90] (Figure 6d).
The use of hydrophobic barriers has been explored for preventing cross-contamination between
adjacent reagent areas. Patterning of wax, silicones, paraffin, and other materials has been used to
separate and guide fluids in a paper strip, facilitating multiplexing. Wax patterning has been popular
as it can be achieved by many different approaches, such as screen printing, dipping, and dripping.
Commercially based wax printers have been leveraged to facilitate patterning of structures, but recently
these systems have been discontinued,
When reactions necessary for an immunoassay are run on a lateral flow strip, it is similar to a
single pot reaction. Control of the sequence of events is not possible as the geometry of the strip is
fixed, and usually single lane. However, the introduction of architectures to the paper can result in
novel control methods. Two-dimensional paper networks (2DPN) are strategically shaped strips, with
incorporated structures that act as valves to enable timing of flow. Fluidic disconnects can be used
control fluid arrival times and shut off times [90]. This can result in the sequential delivery of reagents
to optimize reaction efficiency and thus assay sensitivity [80].
On the fly customization can be achieved by employing a LEGO-block like system [85]. This is a
recently developed strategy called Asynchronous Modular Paperfluidic Linear Instrument-free (Ampli),
which involves the use of blocks to construct a custom flow arrangement on demand (Figure 6e).
Traditional LFAs are constructed of a sample pad, conjugate pad, test area, and wick that are fused
together (Figure 1) and the end user receives them as a monolithic device. However, modularizing
the device allows the user to vary reaction timing, swapping out of different test areas and reagents,
and introduce a desired degree of multiplexing. In an Ampli set, each of the components of the LFA is
put on a modular block, and blocks can be easily snapped together in desired configurations to form
different numbers of branches for multiplexing, test lane lengths, and incorporate different elements,
such as different assays. In addition, Ampli blocks can be dynamically assembled and disassembled,
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enabling timing of the reagents to maximize signal, or back and forth flow to increase immunoassay
test line intensity (Figure 6e).
5.1.2. NP Enhancements
Readout of LFAs is preferably achieved by visualization of the test area due to the accumulation
of the NPs, but this can have a limited sensitivity as readout is by eye. Because nanomaterials have
many unique size and material dependent properties, different types of probes have been used to
enhance the signal intensity in paper-based assays. Increased sensitivity can increase the accuracy of
diagnostics or result in earlier detection of diseases. In addition, the unique properties of nanomaterials
can be used to introduce new capabilities to paper-based tests, as the materials for the NP probe are
broad [14,26,40,41,46,47,70,91–93].
Table 2. Novel readout strategies applied in paper based immunoassays.
Classification LOD Linear Range Advantages Limitations References
Optical readout ng/mL range ng/mL to ug/mL
Quick
Single step run
Inexpensive
Easy to operate
anywhere
Low sensitivity for certain
applications [82]
Optical enhancers
- Isotachophoresis 60–400 foldimprovement 0.1–10 mg/L Improved
sensitivity
Easy to operate
Signal depletion over time [94]
- NP aggregation 1000 foldimprovement 0.5 pM–50 nM
Additional operation step,
less robust to climate
conditions
[44]
- secondary probe
51 (96), 100 (95),
1000 (97) fold
improvement
0.01–30 ng/mL Additional binding event [95–97]
- probe growth 100-fold(99,100)
1010–1013 RNA
copies
Less control in probe
growth between samples [98–100]
Fluorescence readout ng-pg/mLrange
ng/mL to
10 µg/mL
Up to 1000-fold
improvement
(94)
Special equipment
required, access to
electricity
[94,101,102]
SERS ng/mL (81,105) 1–100 ng/mL,102–106 cfu/mL
Up to
10000-fold
improvement
(105)
Expensive equipment and
trained personnel [82,103,104]
Electrochemical ng-µg/mL 0.1–1.0 ng/mL [105,106]
Thermal contrast nM range 10−7 to 10−2 titer [107,108]
Enhanced optical. A major drawback of colorimetric readouts is their relatively high LOD.
Post processing techniques can lower the LOD of optical readout systems. Test line intensity can be
increased by silver staining of the lines lines or isotachaphoresis [94]. Other approaches using NP
aggregation [44], secondary probe binding [95–97], probe growth [98–100], can also increase signal.
In addition, the colorimetric change of gold NPs when they aggregate has been leveraged to generate
assays that change color from red to blue upon analyte binding [65].
Fluorescence readouts can increase sensitivity and lower LOD (Figure 7c). Equipment for reading
fluorescent signals is more common and thus cheaper, and single wavelength excitation and emission
can further reduce technological requirements. However, fluorescence signals are sensitive to intrinsic
and extrinsic conditions, such as salinity, pH, solvation environment of the dye, and so on. Commonly
used materials are silica [101], quantum dots [109] and carbon dots [91] and upconverting NPs
(UCNPs) [102].
NPs have size and shape dependent optical absorption spectra, which means that NPs of different
colors can be used as immunoprobes. Using silver NPs of different colors can enable multiplexing
in a single lane [21,54]. NPs of different colors are conjugated to antibodies for different biomarkers,
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result in different colored test lines depending on the antigen present, which was demonstrated for
differentiation between dengue, yellow fever, and Ebola biomarkers (Figure 7a). The multicolor
properties of NPs has also enabled the use of “barcode” particles [110] which uses NPs of different
colors at predefined ratios to enable even greater multiplexing.
SERS. Surface enhanced Raman spectroscopy (SERS) is a technique where the Raman signal
of a reporter molecule is amplified by the presence of a metal NP effectively reducing their LOD.
Although a spectrometer or microscope is required for test readout, there are a number of advantages
of this methodology. This lowers assay LOD [27,82,103,104] and enables multiplexing capabilities for
multiple targets by simply changing the reporter molecule [22,111]. The “nanotag” format has been
useful for biological detection, where a small molecule reporter is conjugated to a gold NP, and the NP
linked to an antibody specific to a target. For a multiplexed Zika and dengue test, SERS can improve
sensitivity to reach LODs as low as 0.72 ng/mL for Zika and 7.67 ng/mL for dengue NS1, which are
physiological levels for Zika NS1.
Electrochemical. Electrochemical impedance spectroscopy (EIS) is a label free methodology
with a relatively low sensitivity where the detection molecule is bound to a conducting surface.
Concentration of the target molecule is read as the difference between the system voltage phasor and
the measured phasor [105,106]. Ge et. al. proposed an electrochemical sensor where they wax printed
a 6 x 4 grid, where each of the detection sites were functionalized with chitosan, multiwalled carbon
nanotubes and bovine serum albumin (BSA) prior to antibody printing. After antigen binding they
used a functionalized multi walled carbon nanotube to amplify the observed change in signal [37].Sensors 2018, 18, x FOR PEER REVIEW  14 of 25 
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Thermal contrast. The photothermal properties of gold NPs can also be used to enhance the test
line, where excitation of the test line with a laser and a thermal camera readout results in higher contrast
relative to the background. This methodology takes advantage of the ability of metal NPs to interact
with light to generate heat. Qin et. al. were able to improve LOD of an LFA by irradiating the sample
with a laser (λ = 532 nm) and measuring the signal using an infrared camera [107]. Zhan et. al. used
thermal contrast to improve test LOD expand test readability to approximately 6 log10 concentration
range (Figure 7b) [108].
5.1.3. Application of External Readout or Quantification Devices
External devices or readout aids are applied to paper-based assays if the readout methodology is
not visual, e.g., fluorescent, to improve the sensitivity and selectivity or to quantify the result. Such
rigs can often employ low-cost, rugged hardware and leverage mobile phone hardware, combined
with new software to facilitate the development of affordable, standalone instruments that can provide
automated and quantitative measurements of the assays [112,113]. Integrated GPS systems can tag
data with geolocation and time to enable mapping of results, which would help centralized tracking
of diseases and outbreaks [114]. For example, mobile phones have been used to quantify the results
of paper-based assays to detect bioagents in full blood [115], mercury in tap water [116], thyroid
stimulating hormone [117], vitamin D quantification [118], toxins in agriculture [28], among many
others [45,119].
6. Challenges of Paper-Based Assays
The core requirement for paper-based assay functionality is to have a readable signal. Beyond the
ability to bind the target molecule, which is assumed for the purposes of this section, the challenges
that paper-based assay technology faces are related to test sensitivity and specificity. An ideal test
would have high sensitivity, i.e., be able to yield signal in response to physiological concentrations
of the target molecule, while not producing a signal for via aggregation, physical adsorption, cross
reactivity or other factors. This can be translated to sufficient immunoprobes successfully binding to
the printed capture molecule in a specific recognition event, generating a signal.
We have described the test line intensity semi-quantitatively as a function of multiple parameters
(Figure 8) [120]. The signal depends on (i) the biomarker concentration; (ii) physical properties of
the nanoparticle, which includes its concentration, extinction coefficient ε; (iii) the ability of the
immunoprobe to bind the ligand as it relates to its surface chemistry; (iv) the amount of immobilized
antibody; and (v) the target-detector affinity K [36,108].
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6.1. Challenges Associated with the Biological Reagents
Another challenge is that the antibodies, proteins, peptides, nucleic acids which act as binding
species for the target can exhibit cross-reactivity for similar biomarkers. This can result in false positives
for a closely related disease (i.e., a patient infected with Zika results in a positive test for dengue).
This can be a difficult issue to solve if the biomarkers are similar, such as for the NS1 for different
flaviviruses. Increased stringency for antibody screening can be used to decrease cross-reactivity.
On the other hand target molecules not associated with the immunoprobe can compete with
immunoprobe bound antigen for the printed antibody, thus reducing the signal or producing a false
negative. A similar effect may be observed due to cross-reactivity of the printed antibody (Figure 9).
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6.2. Substrate Related Challenges
While a relatively simple substrate when compared to cells, 3D cultures or tissues, hence its
popularity, paper does present a number of challenges which need to be understood and considered
when designing, working with or analyzing paper-based assays. As discussed earlier, the porosity,
wetting angle and additives are important considerations. Others, such as substrate fragility are both
of benefit and potential pitfall as paper may get indented, damaged or even torn as the tensile strength
of unsupported paper strips is ~ 5 N/cm depending on thickness and porosity [53]. Some commercial
papers have coats or covers to support or improve specific qualities of the material. Those, as well as
the interactions between the paper and coat, need to be taken into account during strip design and
preparation as they have a substantial impact on the results.
Paper properties can also affect performance (Figure 9). The conversion of cellulose to
nitrocellulose reduces paper wetting angle so molecules (e.g., PEG) and other modifications are
added to improve substrate properties, such as paper wetting time and importantly adhesion of the
printed detector molecule [75,121]. Paper modifications can impact the adsorption rate of any printed
detection molecules [49,121,122]. Such alterations can also impact sample, antigen and immunoprobe
adhesion and nonspecific binding, as well as possible denaturation [49,121,122]. Thus, knowing the
amount and type of paper additives resulting from production is key to comparing paper-based tests
made with substrate of different origin.
Paper properties can be used to improve strip design so that it incorporates multiple processes
simultaneously. For example, Lu et. al. developed a paper-based system which can detect ferritin
from full blood using a series of papers with different pore sizes. The authors found the methodology
comparable in quality to standard centrifugation for blood separation [123].
6.3. Probe Related Challenges
While introducing NPs does simplify paper-based assay readout and widen applicability it also
presents a number of challenges (Figure 9).
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Immunoprobe interface. Immunoprobes need to be colloidally stable in storage of different
conditions of humidity, temperature and sample content to a degree which allows for reliable test
results. Colloidal stability is dependent on both NP core and surface properties. As the core is
typically chosen for specific physical properties, colloidal stability can be achieved through surface
modifications [66,124–126]. In complex media, NP stability and properties are less dependent on
surface charge and more on variables, including the presence, type and density of a ligand, due to
molecular adsorption, and reduced Debye length [125,127–132].
It is generally accepted that the surface of nanomaterials entering into a solution will rapidly be
decorated with various indigenous molecules. If the solution is biological the adsorbed molecules are
referred to as the “biomolecular corona;” if the solution is environmental the term “natural organic
matter” (NOM) and “NOM corona” is often used.
Understanding the process of molecular adsorption, as well as its consequences is one of the major
avenues of investigation in the field of nanotechnology [133]. The physical and chemical properties
of nanomaterials (size, shape, surface chemistry) influence the properties of the corona that forms.
As a result, understanding and controlling the NP surface interface, otherwise referred to as the
biotic-abiotic or nano-bio interface, has large bearing on the NP material properties and behavior
in vitro and in vivo, including its ability to bind antigens in paper-based assays [36,66,134,135].
Protein coronas and nano-bio interfaces have been studied extensively for when NPs are used as
drug delivery vehicles or imaging agents for cancer. However, these interface issues are also present in
paper-based assays, as NPs are also in a complex biological fluid when the samples are run (Figure 9).
Arguably, the complexity of the interface is greater in paper-based assays. The grafted antibody can
denature, be oriented incorrectly for antigen binding [136,137], or be obscured by the NP surface
ligand. The biological fluid is under flow in a highly obstructed medium with pore size comparable to
that of the immunoprobe, as it wicks through the strip antibody-antigen binding is not at equilibrium.
This could lead to probe aggregation, non-specific adsorption, and steric hindrance of the antibody
on the NP surface. All of these interface issues can detract from assay function, compromising its
specificity and sensitivity and cause unwanted side effects, such as poor signal to noise.
In a diagnostic, non-specific adsorption is critical, because it can result in false positives or
negatives, which can have serious consequences. For example, a false positive for Ebola virus would
mean that the patient could be quarantined with other infected Ebola patients, because of its facile
human-to-human transmission.
Surface ligands are often used to mitigate interactions on the nano-bio interface and impart
desirable properties, such as resistance to protein binding [124,138,139]. Furthermore, the functionality
of surface bound detector molecules has previously been linked to the properties of ligands under or
around them [126,128,138]. However, surface ligands may also sterically hinder the antibody on the
NP surface of the immunoprobe, reducing its ability to bind to the antigen.
6.4. Environment Related Challenges
Environmental factors have the potential to severely impact the commercial applicability of
paper-based assays. The environmental conditions at which the diagnostics are run can often differ
significantly from laboratory conditions. Tropical areas have higher temperatures and humidity which
can compromise test stability. If the antibodies in the test are not stabilized, then may denature under
these conditions (Figure 9). To address this, packaging can help stabilize the device, or stabilizers can
be added to the tests to improve the stability of the biologics.
6.5. Sample Related Challenges
All of the challenges listed above are related to the probability of the immunoprobe to bind the
target molecule in the scenario of a real patient or field sample. It is increased by the number of
functional detector molecules on a structurally and colloidally stable immunoprobe and reduced by
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crosslinking and interference by other molecules. To this end, several sample-related factors need to be
considered during test design.
Type of sample. One important factor is the sample type, e.g. blood or urine, due to the varying
concentration of some target molecules and sample conditions. General protein content and type,
salinity and pH vary in different sample types which may need to be accounted for in the immunoprobe
design. Target biomarkers can have different concentration ranges in different sample types (i.e., high
in blood but low in saliva).
Patient-to-patient sample variability. Factors, such as age, sex and medical history, would impact
test results. As mentioned above, detection of anti-OspA may be the result of previous vaccination or
infection as IgGs can persist months and years after the infection is cleared [58].
Sample variability. Sample content may vary for the same patient due to diet, time and content
of last meal, alcohol or medication intake, disease cycle, immune response, etc. For example, immune
response to an infection is time dependent, in early stages IgM levels for the antigen are high,
but decrease with time. IgG production starts later, but may persist for a long time.
Sample handling. Assay results are also influenced by sample handling, storage, and testing
conditions, as these influence not only the structure of the target molecule but also the test behavior
(flow rate, etc.). The time of testing, sample storage, time outside of storage prior to testing (to allow
for temperature equilibration for example) and time of incubation with the immunoprobe may also be
relevant (Figure 9).
As sample related challenges are highly complex, it can be useful to consider them first.
For example, in a test for an infectious disease the first step would be to consider its cycle as this would
key to finding targets to detect, the type of sample they are in, concentration and state. This would be
crucial for immunoprobe and test design and initial development stages.
7. Conclusions and Future Prospects
There are many exciting future directions for paper-based assays. Infectious diseases are spreading
and occurring with a higher prevalence, leading to projected increases in burdens for many diseases.
Consequently, it is anticipated that there will be a greater need for rapid diagnostics for new and
emerging outbreaks. Even as vaccines and drugs are developed, the need for a diagnostic still remains
for proper patient treatment.
In addition, paper-based assays have many potential application spaces beyond infectious disease,
including drug testing, food safety, counterfeit detection, and many others. Indeed the possibility
of coupling simple, user friendly devices with state-of-the-art communication technology (such as
smart phones) could allow for real time monitoring of disease outbreaks, as well as lower the cost
and simplify long term monitoring of public health concerns, e.g., blood cholesterol [140]. Outside of
healthcare such technology would help governments monitor and control food pathogens, harmful
substances [141], and regulatory adherence. Thus, further developments and wide scale deployment of
POC devices can substantially change how we understand healthcare, agricultural and environmental
regulation, harmful substance control among others.
While the operation of paper-based assays are simple, their operational details are multifaceted.
The applicability of paper-based assays can be determined by parameters starting from the direction
of the paper cutter during manufacturing and the amount of water used during the pulping process to
the details of the nano-bio interface on the immunoprobe and how it interacts with environmental
components, as well as the running conditions of the test. Furthermore, there are multiple strategies
which can enhance the ability of these tests to successfully detect a target molecule, such as improving
probe stability or using signal enhancement. This wide dependence can result in much of the assay
development process being ad hoc which has been a successful in -lab strategy allowing for the quick
development of tests for hundreds of target molecules. However, it is unlikely that this success can be
translated into a large-scale R&D production of commercially viable devices without at least a partial
understanding of a broad enough range of the above parameters. Furthermore, strategic use of such
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data may allow for advanced designs which can relatively easily and cheaply conduct a multistep
analysis in a single device.
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